Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
1. A compound represented by a formula:
wherein:
L is CH 2 ;
R 1 is optionally substituted cyclic C 3 H 5 , wherein the optional substituent of R 1 is CF 3 ;
R 2 is optionally substituted cyclobutyl;
R 3 is optionally substituted C 3 alkyl, wherein the optional substituent of R 3 is OH;
R 4 is H; and
R 5 is H.
2. A composition comprising a compound of claim 1 , wherein the composition is pharmaceutically acceptable.
3. A pharmaceutical dosage form comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
4. A method of activating a Kv7 potassium channel comprising administering an effective amount of a compound of claim 1 to a mammal in need thereof.
5. A method of treating a disorder comprising administering an effective amount of a Kv7 potassium channel activator compound of claim 1 to a mammal in need thereof, wherein the disorder is selected from epilepsy, pain, migraine and tinnitus.
6. The method of claim 5 , wherein pain is selected from neuropathic pain, inflammatory pain, persistent pain, cancer pain and postoperative pain.
7. A compound represented by a formula:
wherein:
L is CH 2 ;
R 1 is optionally substituted C 2 alkyl, wherein the optional substituents of R 1 are independently CF 3 or CH 3 ;
R 2 is optionally substituted cyclobutyl;
R 3 is optionally substituted C 3 alkyl, wherein the optional substituent of R 3 is OH;
R 4 is H; and
R 5 is H.
8. A composition comprising a compound of claim 7 , wherein the composition is pharmaceutically acceptable.
9. A pharmaceutical dosage form comprising a compound of claim 7 and a pharmaceutically acceptable excipient.
10. A method of activating a Kv7 potassium channel comprising administering an effective amount of a compound of claim 7 to a mammal in need thereof.
11. A method of treating a disorder comprising administering an effective amount of a Kv7 potassium channel activator compound of claim 7 to a mammal in need thereof, wherein the disorder is selected from epilepsy, pain, migraine and tinnitus.
12. The method of claim 11 , wherein pain is selected from neuropathic pain, inflammatory pain, persistent pain, cancer pain and postoperative pain.